APPEN
7.3.2019 17:02:08 CET | Business Wire | Press release
Appen Limited today announced the achievement of ISO/IEC 27001:2013 accreditation for its facility in Cavite, Philippines to meet the rapidly growing demand for human-annotated datasets used by companies worldwide to train machine learning and artificial intelligence (AI) applications.
The facility was established to ensure commercial confidentiality and better support privacy management. Globally recognized, the ISO/IEC 27001:2013 standard defines the requirements for an Information Security Management System (ISMS), and a process-based approach for establishing, implementing, operating, monitoring, maintaining and improving the ISMS.
ISO/IEC 27001:2013 accreditation underpins Appen’s ability to work on datasets for clients that contain personally identifiable information – data that could potentially identify a specific individual – as well as other sensitive material, such as data related to new product development.
“Appen’s facility in the Philippines gives clients enhanced options to scale their AI programs with the assurance that their sensitive data and projects will remain secure,” said Mark Brayan, Appen’s chief executive officer. “It’s the perfect complement to our high-security facility in the U.K., and is an important part of our suite of secure at-home and in-facility solutions.”
Appen works with the world’s leading technology companies, as well as firms across all industries to provide high-quality data for their machine learning programs. Appen’s suite of secure solutions includes secure facilities as well as secure remote worker options designed to scale customers’ machine learning programs while maintaining data privacy. Use case examples range from voice recognition in smart speakers to geospatial analysis in self-driving cars, to intelligent search and online advertising results.
Industry analysts estimate the data collection and annotation market will be worth up to $19 billion – approximately 10% of the overall AI market – by 2025. The explosive growth is attributed to the need for high volumes of annotated data that are required to improve AI algorithm accuracy. Today, approximately one-third of AI applications require frequent or monthly data updates, and one-quarter of those need weekly updates, according to McKinsey Global Institute.
Datasets created by Appen include image, text, audio, video and relevance data, as well as speech and natural language data from over 130 countries and more than 180 languages and dialects.
The announcement today follows Appen’s recent reporting of record results of AU$364.3 million in 2018, representing 119% growth year-over-year.
During the company shareholder call last week, Brayan outlined Appen’s 2019 growth initiatives that include increasing technology development to improve the productivity of its global crowd of over 1 million skilled contractors who develop the AI training datasets in conjunction with Appen’s Client Services team. In addition to expanding Appen’s secure solutions, the company also plans to increase its full-time staff and investments in China, the largest AI market outside of the U.S.
Founded in 1996, Appen has office locations worldwide including Seattle, San Francisco, Detroit, and Beijing in addition to the Philippines, U.K. and its headquarters in Sydney.
About Appen
Appen is a global leader in the development of high-quality, human-annotated datasets for machine learning and artificial intelligence. Appen brings over 20 years of experience capturing and enriching a wide variety of data types including speech, text, image, and video. With deep expertise in more than 180 languages and access to a global crowd of over 1 million skilled contractors, Appen partners with technology, automotive and e-commerce companies — as well as governments worldwide — to help them develop, enhance and use products that rely on natural languages and machine learning.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005137/en/
Contact:
Jodie Ruby VP of Marketing jruby@appen.com 425-442-8014
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 14:23:00 CEST | Press release
The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, w
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release
AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release
New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr
Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release
Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 202616.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
